209 related articles for article (PubMed ID: 24498052)
1. Inhibition of nucleotide biosynthesis potentiates the antifungal activity of amphotericin B.
Banerjee D; Burkard L; Panepinto JC
PLoS One; 2014; 9(1):e87246. PubMed ID: 24498052
[TBL] [Abstract][Full Text] [Related]
2. Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans.
Yang F; Gritsenko V; Lu H; Zhen C; Gao L; Berman J; Jiang YY
Microbiol Spectr; 2021 Oct; 9(2):e0072321. PubMed ID: 34585947
[TBL] [Abstract][Full Text] [Related]
3. Identification of Off-Patent Drugs That Show Synergism with Amphotericin B or That Present Antifungal Action against Cryptococcus neoformans and
Rossi SA; de Oliveira HC; Agreda-Mellon D; Lucio J; Mendes-Giannini MJS; García-Cambero JP; Zaragoza O
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988099
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Oral Encochleated Amphotericin B in a Mouse Model of Cryptococcal Meningoencephalitis.
Lu R; Hollingsworth C; Qiu J; Wang A; Hughes E; Xin X; Konrath KM; Elsegeiny W; Park YD; Atakulu L; Craft JC; Tramont EC; Mannino R; Williamson PR
mBio; 2019 May; 10(3):. PubMed ID: 31138748
[No Abstract] [Full Text] [Related]
5. Combined in vitro activity of amphotericin B and 5-fluorocytosine against Cryptococcus neoformans and Candida albicans.
Chen HH; Liushih RN; Hsieh WC
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1982 May; 15(2):106-12. PubMed ID: 7047097
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effect of the verapamil and amphotericin B against Cryptococcus neoformans.
Pereira TC; do Carmo PHF; de Menezes RT; de Oliveira HC; de Oliveira LD; Junqueira JC; Scorzoni L
Folia Microbiol (Praha); 2023 Dec; 68(6):999-1004. PubMed ID: 37950840
[TBL] [Abstract][Full Text] [Related]
7. Dectin-2-Targeted Antifungal Liposomes Exhibit Enhanced Efficacy.
Ambati S; Ellis EC; Lin J; Lin X; Lewis ZA; Meagher RB
mSphere; 2019 Oct; 4(5):. PubMed ID: 31666315
[No Abstract] [Full Text] [Related]
8. In vitro and in vivo studies on synergistic antifungal activity.
Shadomy S
Contrib Microbiol Immunol; 1977; 4():147-57. PubMed ID: 342191
[No Abstract] [Full Text] [Related]
9. Evaluation of amphotericin B and flucytosine in combination against Candida albicans and Cryptococcus neoformans using time-kill methodology.
Keele DJ; DeLallo VC; Lewis RE; Ernst EJ; Klepser ME
Diagn Microbiol Infect Dis; 2001 Nov; 41(3):121-6. PubMed ID: 11750164
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine.
Mitsuyama J; Nomura N; Hashimoto K; Yamada E; Nishikawa H; Kaeriyama M; Kimura A; Todo Y; Narita H
Antimicrob Agents Chemother; 2008 Apr; 52(4):1318-24. PubMed ID: 18227186
[TBL] [Abstract][Full Text] [Related]
11. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.
Dannaoui E; Abdul M; Arpin M; Michel-Nguyen A; Piens MA; Favel A; Lortholary O; Dromer F;
Antimicrob Agents Chemother; 2006 Jul; 50(7):2464-70. PubMed ID: 16801427
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.
Schwarz P; Dromer F; Lortholary O; Dannaoui E
Antimicrob Agents Chemother; 2006 Jan; 50(1):113-20. PubMed ID: 16377675
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility of coccidioides immitis, Candida albicans, and Cryptococcus neoformans to amphotericin B, flucytosine, and clotrimazole.
Hoeprich PD; Huston AC
J Infect Dis; 1975 Aug; 132(2):133-41. PubMed ID: 1099147
[TBL] [Abstract][Full Text] [Related]
14.
Banerjee D; Umland TC; Panepinto JC
mSphere; 2016; 1(6):. PubMed ID: 27904878
[TBL] [Abstract][Full Text] [Related]
15. Interactions between triazoles and amphotericin B against Cryptococcus neoformans.
Barchiesi F; Schimizzi AM; Caselli F; Novelli A; Fallani S; Giannini D; Arzeni D; Di Cesare S; Di Francesco LF; Fortuna M; Giacometti A; Carle F; Mazzei T; Scalise G
Antimicrob Agents Chemother; 2000 Sep; 44(9):2435-41. PubMed ID: 10952592
[TBL] [Abstract][Full Text] [Related]
16. In vitro studies with combinations of 5-fluorocytosine and amphotericin B.
Shadomy S; Wagner G; Espinel-Ingroff E; Davis BA
Antimicrob Agents Chemother; 1975 Aug; 8(2):117-21. PubMed ID: 1101814
[TBL] [Abstract][Full Text] [Related]
17. Amphotericin B and amphotericin B methyl ester ascorbate. I. Chemotherapeutic activity against Candida albicans, Cryptococcus neoformans, and Blastomyces dermatitidis in mice.
Gadebusch HH; Pansy F; Klepner C; Schwind R
J Infect Dis; 1976 Nov; 134(5):423-7. PubMed ID: 792355
[TBL] [Abstract][Full Text] [Related]
18. The in vitro effects of interferon-gamma, alone or in combination with amphotericin B, tested against the pathogenic fungi Candida albicans and Aspergillus fumigatus.
El-Khoury M; Ligot R; Mahoney S; Stack CM; Perrone GG; Morton CO
BMC Res Notes; 2017 Aug; 10(1):364. PubMed ID: 28764751
[TBL] [Abstract][Full Text] [Related]
19. The in-vivo activity of an antifungal antibiotic, benanomicin A, in comparison with amphotericin B and fluconazole.
Ohtsuka K; Watanabe M; Orikasa Y; Inouye S; Uchida K; Yamaguchi H; Kondo S; Takeuchi T
J Antimicrob Chemother; 1997 Jan; 39(1):71-7. PubMed ID: 9044030
[TBL] [Abstract][Full Text] [Related]
20. The combined effect of 5-fluorocytosine and amphotericin B in the therapy of murine cryptococcosis.
Block ER; Bennett JE
Proc Soc Exp Biol Med; 1973 Feb; 142(2):476-80. PubMed ID: 4570039
[No Abstract] [Full Text] [Related]
[Next] [New Search]
